European Commission Grants Orphan Drug Designation to Soliris(R) (eculizumab) for the Treatment of Patients with Myasthenia Gravis (MG)

CHESHIRE, Conn.--(Healthcare Sales & Marketing Network)--Alexion Pharmaceuticals (ALXN) today announced that the European Commission has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis... Biopharmaceuticals, RegulatoryAlexion Pharmaceuticals, Soliris, eculizumab, Myasthenia Gravis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news